1. Home
  2. RGEN vs ROIV Comparison

RGEN vs ROIV Comparison

Compare RGEN & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RGEN
  • ROIV
  • Stock Information
  • Founded
  • RGEN 1981
  • ROIV 2014
  • Country
  • RGEN United States
  • ROIV United Kingdom
  • Employees
  • RGEN N/A
  • ROIV N/A
  • Industry
  • RGEN Medical/Dental Instruments
  • ROIV Biotechnology: Pharmaceutical Preparations
  • Sector
  • RGEN Health Care
  • ROIV Health Care
  • Exchange
  • RGEN Nasdaq
  • ROIV Nasdaq
  • Market Cap
  • RGEN 8.0B
  • ROIV 7.8B
  • IPO Year
  • RGEN N/A
  • ROIV N/A
  • Fundamental
  • Price
  • RGEN $123.57
  • ROIV $11.28
  • Analyst Decision
  • RGEN Buy
  • ROIV Buy
  • Analyst Count
  • RGEN 12
  • ROIV 4
  • Target Price
  • RGEN $170.40
  • ROIV $17.50
  • AVG Volume (30 Days)
  • RGEN 787.0K
  • ROIV 6.6M
  • Earning Date
  • RGEN 07-29-2025
  • ROIV 08-07-2025
  • Dividend Yield
  • RGEN N/A
  • ROIV N/A
  • EPS Growth
  • RGEN N/A
  • ROIV N/A
  • EPS
  • RGEN N/A
  • ROIV N/A
  • Revenue
  • RGEN $650,429,000.00
  • ROIV $29,053,000.00
  • Revenue This Year
  • RGEN $13.93
  • ROIV $2.64
  • Revenue Next Year
  • RGEN $14.35
  • ROIV $378.09
  • P/E Ratio
  • RGEN N/A
  • ROIV N/A
  • Revenue Growth
  • RGEN 4.88
  • ROIV N/A
  • 52 Week Low
  • RGEN $102.97
  • ROIV $8.73
  • 52 Week High
  • RGEN $182.52
  • ROIV $13.06
  • Technical
  • Relative Strength Index (RSI)
  • RGEN 48.29
  • ROIV 53.61
  • Support Level
  • RGEN $115.86
  • ROIV $11.25
  • Resistance Level
  • RGEN $126.61
  • ROIV $11.82
  • Average True Range (ATR)
  • RGEN 4.43
  • ROIV 0.33
  • MACD
  • RGEN -0.07
  • ROIV -0.00
  • Stochastic Oscillator
  • RGEN 42.95
  • ROIV 52.97

About RGEN Repligen Corporation

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

About ROIV Roivant Sciences Ltd.

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Share on Social Networks: